Drugs / CD45RA-depleted peripheral blood mononuclear cells
CD45RA-depleted peripheral blood mononuclear cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02337595 | Aug 2014 → Mar 2015 | T lymphoblastic leukemia/lymphoma, acute myeloid leukemia, bone marrow failure syndrome, graft versus host disease +2 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02942173 | Oct 2016 → Aug 2019 | graft versus host disease, leukemia, lymphoma, myelodysplastic syndrome | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD45RA-depleted peripheral blood mononuclear cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02337595 ↗ |
| Modality | Cell therapy | “Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells” NCT02337595 ↗ |